Starting PAH treatment: one drug first or two drugs together?
Treatments studied
Part of Lungs & breathing clinical trials.
This study compares starting with one medication versus two medications together for people with pulmonary arterial hypertension (PAH). It aims to find out which approach works better for low- or intermediate-risk patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and weigh at least 88 pounds (40 kg).
- You have been diagnosed with a specific type of PAH (idiopathic, hereditary, or related to conditions like scleroderma or corrected heart defects).
- Your PAH is assessed as low or intermediate risk based on standard guidelines.
- You have not taken any PAH medications in the past 4 weeks.
- You can walk at least 100 meters (about the length of a football field) without stopping.
- You have not participated in a cardiopulmonary rehab program in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares starting with two oral medications versus one for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have conditions like high blood pressure, diabetes, obesity, or heart disease. The goal is to see if a two-drug approach works better for patients with these additional health issues.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This study tests a drug called ambrisentan for people with very early, low-risk pulmonary arterial hypertension (PAH). If you have a mild form of PAH and haven't yet taken other PAH medications, this trial might help slow the progression of your condition.
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
Hear when a new Pulmonary Arterial Hypertension (PAH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.